News & Updates

Artificial pancreas supports glucose control, even in ‘terrible twos’

06 Jul 2021 by

An automated insulin delivery system, also referred to as artificial pancreas, helps improve glycaemic control in children with type 1 diabetes (T1D) in a study presented at ADA 2021.

Artificial pancreas supports glucose control, even in ‘terrible twos’

06 Jul 2021

Sotagliflozin shortens hospital stay, improves survival in T2D patients with worsening heart failure

05 Jul 2021

Treatment with sotagliflozin in hospitalized patients with type 2 diabetes (T2D) leads to an increase in the number of days alive and out of the hospital (DAOH), a metric that may provide an additional patient-centred outcome to capture the totality of disease burden, reports a study.

Sotagliflozin shortens hospital stay, improves survival in T2D patients with worsening heart failure

05 Jul 2021

Longer screen time makes kids big around the belly

05 Jul 2021

A recent Singapore study reports that the longer children are engaged with screens, the higher their likelihood of developing abdominal obesity. This is especially true for boys and those of Malay ethnicity.

Longer screen time makes kids big around the belly

05 Jul 2021

Abdominal obesity doubles liver cancer risk in CHB patients

03 Jul 2021

Excessive accumulation of fat in the abdominal area contributes to a twofold increase in the risk of developing hepatocellular carcinoma (HCC) among chronic hepatitis B (CHB) patients being treated with antivirals, as shown in a study.

Abdominal obesity doubles liver cancer risk in CHB patients

03 Jul 2021

Once-weekly semaglutide for T2D good enough in real-world use

02 Jul 2021 by

A once-weekly dosing of the glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide for type 2 diabetes (T2D) passes muster in real world, conferring benefits for blood sugar and weight across adult patients with varying characteristics and background medication, according to the Denmark (DK)/Sweden (SE) data from the SURE programme.

Once-weekly semaglutide for T2D good enough in real-world use

02 Jul 2021

Fenofibrate cardioprotective, cuts risk of death in T2D

01 Jul 2021

In patients with type 2 diabetes (T2D), treatment with fenofibrate appears to lower the incidence of cardiovascular events, as well as the rate of total and cardiac mortality, according to data from a large study.

Fenofibrate cardioprotective, cuts risk of death in T2D

01 Jul 2021

$Cabozantinib a new SoC for previously treated RAI-refractory DTC?$

Cabozantinib a new SoC for previously treated RAI-refractory DTC?

30 Jun 2021 by

In individuals with radio-iodine-refractory differentiated thyroid cancer (RAI-refractory DTC) who have progressed during/after prior VEGFR-targeted therapy, the VEGFR2/MET/AXL/RET inhibitor cabozantinib showed a significant progression-free survival (PFS) benefit, according to findings of the phase III COSMIC-311 trial presented at ASCO 2021.

Cabozantinib a new SoC for previously treated RAI-refractory DTC?

30 Jun 2021

DPP-4 inhibitors a suitable second-line treatment for young-onset diabetes

30 Jun 2021

In the treatment of patients with young-onset diabetes, adding dipeptidyl peptidase-4 (DPP-4) inhibitors contributes to lower risks of hospitalization and death compared with sulfonylureas, according to a study.

DPP-4 inhibitors a suitable second-line treatment for young-onset diabetes

30 Jun 2021

Weight-loss surgery slims down cancer risk in NAFLD patients

29 Jun 2021 by

Nonalcoholic fatty liver disease (NAFLD) patients with morbid obesity who undergo bariatric surgery are less likely to develop cancer than their peers who did not go through the procedure, as shown in a study.

Weight-loss surgery slims down cancer risk in NAFLD patients

29 Jun 2021

Plant-based protein diet lowers serum urate in gout patients

29 Jun 2021

A Dietary Approaches to Stop Hypertension (DASH)-style diet with an emphasis on plant-based protein reduces serum urate relative to that rich in carbohydrates or unsaturated fat, reports a recent study.

Plant-based protein diet lowers serum urate in gout patients

29 Jun 2021

News & Updates

Filter by Specialty:

Specialty:

Artificial pancreas supports glucose control, even in ‘terrible twos’

Artificial pancreas supports glucose control, even in ‘terrible twos’

Sotagliflozin shortens hospital stay, improves survival in T2D patients with worsening heart failure

Sotagliflozin shortens hospital stay, improves survival in T2D patients with worsening heart failure

Longer screen time makes kids big around the belly

Longer screen time makes kids big around the belly

Abdominal obesity doubles liver cancer risk in CHB patients

Abdominal obesity doubles liver cancer risk in CHB patients

Once-weekly semaglutide for T2D good enough in real-world use

Once-weekly semaglutide for T2D good enough in real-world use

Fenofibrate cardioprotective, cuts risk of death in T2D

Fenofibrate cardioprotective, cuts risk of death in T2D

Cabozantinib a new SoC for previously treated RAI-refractory DTC?

Cabozantinib a new SoC for previously treated RAI-refractory DTC?

DPP-4 inhibitors a suitable second-line treatment for young-onset diabetes

DPP-4 inhibitors a suitable second-line treatment for young-onset diabetes

Weight-loss surgery slims down cancer risk in NAFLD patients

Weight-loss surgery slims down cancer risk in NAFLD patients

Plant-based protein diet lowers serum urate in gout patients

Plant-based protein diet lowers serum urate in gout patients